SEL-120 Drug Asset Due Diligence Report 2026

This SEL-120 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether SEL-120 can convert its Small molecule drug profile and CDK19 x CDK8 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	SEL-120 (query alias: SEL-120)
Modality / target	Small molecule drug; CDK19 x CDK8; CDK19 inhibitors, CDK8 inhibitors
Highest global status	Phase 2
Originator	Ryvu Therapeutics SA
Active developers	Ryvu Therapeutics SA

The MCP disease footprint includes Advanced Malignant Solid Neoplasm, Chromosome 5q Deletion Syndrome, Monosomy 7 of Bone Marrow. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06987058	Phase 2	Enrolling by invitation	14	Primary endpoint not disclosed in English source
NCT06397313	Phase 2	Terminated	36	Primary endpoint not disclosed in English source
NCT06268574	Phase 2	Terminated	62	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An open-label, Phase I/II clinical trial of romaciclib (RVU120) as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)

Phase 1/2; n=23; evaluation: Positive. Reported fields: SVR(12-week, ≥35%) = 17.0 % ; SVR(12-week, ≥35%) = 17.0 %

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Phase 2; n=42; evaluation: Positive. Reported fields: AE = 343.0 Event

PRELIMINARY RESULTS FROM RIVER-81, A PHASE 2 STUDY OF RVU120+VEN IN PATIENTS WITH AML FAILING FIRST LINE VEN+HMA

Phase 2; n=36; evaluation: Positive. Reported fields: Adverse Event: Nausea = 41% of the treated patients ; Adverse Event: Nausea = 41% of the treated patients

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

SEL-120 addresses Advanced Malignant Solid Neoplasm, Chromosome 5q Deletion Syndrome, Monosomy 7 of Bone Marrow. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: CDK19 x CDK8.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CDK19 x CDK8 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for producing type 2 innate lymphocytes”. The milestone feed surfaced a patent-application signal described as “Drug combination of FAK inhibitor and immunogenic cell death inducer and use thereof”. The milestone feed surfaced a patent-application signal described as “CDK8/19 inhibitors for preventing drug resistance”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO